drugset / Trial / NCT00315211
Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purposes of this study are: * To determine the overall response rate of patients treated with at least 2 cycles of this regimen. * To determine the feasibility and toxicity of the combination of topotecan and docetaxel.
Timeline
- Start
- 2004-11
- Primary completion
- 2007-06
- Completion
- 2007-11-08
Outcome
Outcome not reported
Stopped (Enrollment): “Slow Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Topotecan | Small molecule | 3 mg/m2 | Intravenous |